ABSI Quote, Financials, Valuation and Earnings

Spectral AI has a net margin of -4358.35% compared to Absci's net margin of -18.4%. Absci's return on equity of -50.63% beat Spectral AI's return on equity of -4727.7%.

Absci has a consensus price target of $8.63, signalling upside risk potential of 259.38%. On the other hand Spectral AI has an analysts' consensus of $5.12 which suggests that it could grow by 326.67%. Given that Spectral AI has higher upside potential than Absci, analysts believe Spectral AI is more attractive than Absci.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spectral AI has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spectral AI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Spectral AI pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are smaller than Spectral AI quarterly revenues of $8.2M. Absci's net income of -$29M is lower than Spectral AI's net income of -$1.5M. Notably, Absci's price-to-earnings ratio is -- while Spectral AI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 58.35x versus 0.75x for Spectral AI. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -4358.35% compared to Absci's net margin of -117.16%. Absci's return on equity of -50.63% beat Moderna's return on equity of -29.09%.

Absci has a consensus price target of $8.63, signalling upside risk potential of 259.38%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 96.76%. Given that Absci has higher upside potential than Moderna, analysts believe Absci is more attractive than Moderna.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are smaller than Moderna quarterly revenues of $956M. Absci's net income of -$29M is higher than Moderna's net income of -$1.1B. Notably, Absci's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 58.35x versus 3.29x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -4358.35% compared to Absci's net margin of -49.65%. Absci's return on equity of -50.63% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Absci has a consensus price target of $8.63, signalling upside risk potential of 259.38%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 45.27%. Given that Absci has higher upside potential than NovaBay Pharmaceuticals, analysts believe Absci is more attractive than NovaBay Pharmaceuticals.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Absci's net income of -$29M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Absci's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 58.35x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -4358.35% compared to Absci's net margin of -3965.99%. Absci's return on equity of -50.63% beat Recursion Pharmaceuticals's return on equity of -77.06%.

Absci has a consensus price target of $8.63, signalling upside risk potential of 259.38%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 76.64%. Given that Absci has higher upside potential than Recursion Pharmaceuticals, analysts believe Absci is more attractive than Recursion Pharmaceuticals.

Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Absci quarterly revenues are $665K, which are smaller than Recursion Pharmaceuticals quarterly revenues of $4.5M. Absci's net income of -$29M is higher than Recursion Pharmaceuticals's net income of -$178.9M. Notably, Absci's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 58.35x versus 23.90x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.